Obesity Trial, Recruiting (NCT07244445)

Obesity Trial, Recruiting NCT07244445 Sponsor: Ian J. Neeland, MD Condition: Obesity

Printed from Voxsanity (voxsanity.com.au) — NCT07244445 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Obesity

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People with a body weight classified as obese (a BMI of 30 or higher), or people with a BMI of 27 or higher who also have at least one health condition related to excess weight, who have been taking semaglutide or tirzepatide continuously for three months for a medical reason and are still taking it at the time of joining the trial

Who may not be able to join:

People who are not currently using a GLP-1 receptor agonist medication, or for whom this type of medication is medically unsuitable
People with a known allergy to nuts
People who are pregnant or currently breastfeeding
People who are incarcerated

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ian Neeland, MD, University Hospitals Cleveland Medical Center

Phone: 216-844-5965

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07244445

Sponsor: Ian J. Neeland, MD

Phase: Not Applicable

Status: Recruiting

Condition: Obesity

Trial contact: 216-844-5965

More information: https://clinicaltrials.gov/study/NCT07244445

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People with a body weight classified as obese (a BMI of 30 or higher), or people with a BMI of 27 or higher who also have at least one health condition related to excess weight, who have been taking semaglutide or tirzepatide continuously for three months for a medical reason and are still taking it at the time of joining the trial

Who may not be able to join:

People who are not currently using a GLP-1 receptor agonist medication, or for whom this type of medication is medically unsuitable
People with a known allergy to nuts
People who are pregnant or currently breastfeeding
People who are incarcerated

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Ian J. Neeland, MD

Registry

ClinicalTrials.gov

Start date

29 January 2026

Est. completion

1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change is Satiety as measured by the Hunger and Satiety Visual Analog Scales (VAS); Change in fatigue as measured by the Fatigue Severity VAS-F Survey; Change in mood/well-being as measured by the Mental clarity, energy levels, and motivation VAS.; Change in dietary quality as measured by Healthy Eating Index (HEI); Change in food enjoyment as measured by the Food Pleasure Scale (FPS); Change in fasting glucose as measured by medical record review; Change in HbA1c as measured by medical record review; Change in total cholesterol as measured by medical record review; Change in LDL-C as measured...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov